|Registry of biomedical companies:
[(]  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 456 active entries
Gaudenzdorfer Guertel 43-45
Vienna, A-1120, Austria
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
ViennaLab is an Austrian company with a successful history in developing, manufacturing and worldwide distributing genetic tests since its foundation in 1990.
ViennaLab StripAssays® and RealFast™ assays are easy, reliable and affordable human in vitro diagnostic tests covering the following fields: inherited diseases, genetic predispositions, pharmacogenetics and oncology.
Assays are offered for Cardiovascular Diseases, Thalassemia, Cystic Fibrosis, Familial Mediterranean Fever, Alzheimer Disease, Sugar Intolerance, among others. Products of the pharmacogenetics and oncology portfolio help to achieve safer and more individualized anticoagulant and cancer therapies.
Based on reverse hybridization, the user-friendly StripAssays® have up to 48 immobilized probes for wild-type and mutated alleles, and are extremely accurate and reliable. The assays use standard laboratory equipment, which makes them easy to implement and the results can be either read by eye, or interpreted with a proprietary scanner-based software (Evaluator). For regular users, automation of the entire teststrip processing is available.
RealFast™ assays are based on TaqMan® real-time PCR technology and allow the rapid and reliable detection of single nucleotide polymorphisms (SNPs) as well as copy number variations (CNV).
All ViennaLab products are manufactured according to the quality standards of ISO 9001, ISO 13485, and are CE/IVD marked. StripAssays® and RealFast™ assays also take part in many international research studies and quality assesment schemes, which allow scientific evidence of the quality employed.
To find out more, please visit www.viennalab.com.
Last update of this entry: March 11, 2019